->Kahtar: Repair CS1 error(s), replaced: website=https://www. → website=www., removed stub tag

2021-09-06T06:49:46Z

Repair CS1 error(s), replaced: website=https://www. → website=www., removed stub tag

New page

{{Use dmy dates|date=August 2018}}
{{Use Indian English|date=August 2018}}
{{more citations needed|date=December 2011}}
{{Infobox company
| name = Rubicon Research Pvt. Ltd.
| type = [[Private Limited company]]
| foundation = {{Start date and age|1999}} <br />[[Mumbai]], [[India]]
| location_city = [[Mumbai]], [[India]]
| location_country = India
| industry = [[Pharmaceutical industry|Pharmaceutical]]
| products = [[Pharmaceutical]]s
| services = Contract Research, Formulation Development (NDDS), Contract Manufacturing & supply chain, Dossier Development ANDA/CTD format
| num_employees = 200 <small>(2010)</small>
| homepage =
}}

'''Rubicon Research''' is an IP led, specialty pharmaceutical company located in Mumbai, India. Its formulation development is across multiple dosage forms, oral solids, oral liquids, nasal, ophthalmic, topical, injectable, fixed dose combinations, and drug device combinations. In 2019 the company received USD 100 million in growth capital investment from General Atlantic, a growth equity firm.<ref>{{Cite web|date=2019-04-09|title=General Atlantic acquires significant shareholding in Rubicon Research|url=https://www.financialexpress.com/industry/general-atlantic-acquires-significant-shareholding-in-rubicon-research/1542230/|access-date=2021-04-29|website=The Financial Express|language=en-US}}</ref>

The company operates out of four locations. The corporate HQ and R&D center is in Thane, India. There's also an R&D center in Concord, Canada, a manufacturing plant located in Ambernath, India, and a regulatory office in Plainsboro, US.

==History and Evolution==

Rubicon Research was founded in 1999 by Pratibha Pilgaonkar, Sudhir Pilgaonkar, and Maharukh Rustomjee. In 2000 it started operations as an independent product development company, located in Bhandup, Mumbai, with three scientists in a {{convert|2000|sqft|m2|abbr=on}} laboratory. It became an outsourcing partner to the global healthcare and pharmaceutical industry. In 2003, the Directorate of Science and Technology, Government of India approved the facilities as a commercial Research and Development (R&D) company.

In 2006-07 Rubicon licensed its Orodispersible excipient, RubiODT to Mallinckrodt Baker, Inc.<ref>Pharmaceutical online : Mallinckrodt Baker And Rubicon Research Sign Agreement For Performance Excipient Development</ref>

In 2009 the company commission an oral solids manufacturing plant in Ambernath, India. The 140,000+ square feet cGM production facility is compliant with US FDA and EU specifications. Rubicon Research started its commercial manufacturing and shipments to the US and Europe in 2015. Rubicon Research was audited by USFDA in March 2015 & Dec 2015, both time they had Zero 483.

In 2012 Rubicon Research signed an agreement with Avantor Performance Materials to develop and market a novel gastro-retentive excipient that enables the delivery of molecules with a window of absorption.<ref>{{Cite web|date=2012-10-16|title=Avantor, Rubicon Research Collaborate on Functional Excipient Development|url=https://www.drugdiscoverytrends.com/avantor-rubicon-research-collaborate-on-functional-excipient-development/|access-date=2021-04-29|website=Drug Discovery and Development|language=en-US}}</ref><ref>{{Cite web|title=Avantor and Rubicon Research to collaborate on novel excipients|url=https://www.manufacturingchemist.com/news/article_page/Avantor_and_Rubicon_Research_to_collaborate_on_novel_excipients/81536|access-date=2021-04-29|website=www.manufacturingchemist.com}}</ref>

In 2016, in Series B funding, the private equity firm Everstone Group bought out the stakes of Kotak Private Equity and Maharukh Rustomjee.<ref>{{Cite news|title=Everstone buys Mumbai-based drug tech firm Rubicon for Rs 220-crore|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/everstone-buys-mumbai-based-drug-tech-firm-rubicon-for-rs-220-crore/articleshow/55033140.cms|access-date=2021-05-12}}</ref><ref>{{Cite web|date=2016-10-24|title=Everstone buys majority stake in Rubicon Research; Kotak PE exits|url=https://www.vccircle.com/everstone-buys-majority-stake-rubicon-research-kotak-pe-exits|access-date=2021-05-12|website=VCCircle|language=en-US}}</ref>

In 2019, Rubicon Research received a USD 100 million growth capital commitment from General Atlantic<ref>{{Cite web|title=Rubicon Research and General Atlantic Announce Strategic Partnership|url=https://www.generalatlantic.com/media-article/rubicon-research-and-general-atlantic-announce-strategic-partnership/|access-date=2021-05-12|website=General Atlantic|language=en-US}}</ref><ref>{{Cite web|last=Dhanjal|first=Swaraj Singh|date=2019-04-08|title=General Atlantic to invest $100 million in Rubicon|url=https://www.livemint.com/companies/news/general-atlantic-to-invest-100-million-in-rubicon-1554740726323.html|access-date=2021-05-12|website=mint|language=en}}</ref> and acquired 15 ANDAs to augment its generic portfolio.<ref>{{Cite web|date=2019-04-09|title=General Atlantic acquires significant shareholding in Rubicon Research|url=https://www.financialexpress.com/industry/general-atlantic-acquires-significant-shareholding-in-rubicon-research/1542230/|access-date=2021-05-12|website=The Financial Express|language=en-US}}</ref><ref>{{Cite web|date=2019-04-01|title=Everstone scores one of its best exits as General Atlantic strikes a control deal|url=https://www.vccircle.com/everstone-scores-one-of-its-best-exits-as-general-atlantic-strikes-a-control-deal|access-date=2021-05-12|website=VCCircle|language=en-US}}</ref>

In 2020 Rubicon Research Private Limited acquired Impopharma Canada Limited with operations in Ontario, Canada, expanding its global development network, and established Rubicon Research Canada Ltd.<ref>{{Cite web|date=2020-01-07|title=Rubicon Research Acquires Impopharma Canada|url=https://www.businesswire.com/news/home/20200107005135/en/Rubicon-Research-Acquires-Impopharma-Canada|access-date=2021-05-12|website=www.businesswire.com|language=en}}</ref><ref>{{Cite web|title=Rubicon Research Acquires Impopharma Canada|url=https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/rubicon-research-acquires-impopharma-canada|access-date=2021-05-12|website=financialpost|language=en-CA}}</ref> The Canadian development facility specializes in the development and testing of pulmonary and nasal drug delivery systems and ophthalmic, otic, and dermal products.

In 2021 the company launched two subsidiaries—Rubicon Consumer Healthcare and Rubicon Academy. Rubicon Consumer Healthcare develops personal wellness, healthcare, and nutrition products and solutions for the Indian market. Rubicon Academy<ref>{{Cite web|date=2020-10-14|title=COVID-19 has made online learning a credible source of education|url=https://www.expresspharma.in/covid-19-has-made-online-learning-a-credible-source-of-education/|access-date=2021-05-12|website=Express Pharma|language=en-US}}</ref> is a learning platform for pharmaceutical professionals and students.

In July 2021, Rubicon Research announced the acquisition of Meditab Specialities Limited’s oral liquid dosage and nasal product manufacturing facility located in Satara, Maharashtra.<ref>{{Cite web|title=Rubicon Research acquires Satara facility of Meditab Specialities|url=https://www.outlookindia.com/newsscroll/rubicon-research-acquires-satarafacility-of-meditab-specialities/2117584|access-date=2021-08-24|website=www.outlookindia.com/}}</ref><ref>{{Cite web|last=Livemint|date=2021-07-09|title=General Atlantic-led Rubicon Research acquires Meditab Specialities|url=https://www.livemint.com/news/general-atlantic-led-rubicon-research-acquires-meditab-specialities-11625822899782.html|access-date=2021-08-24|website=mint|language=en}}</ref><ref>{{Cite news|title=Rubicon Research acquires Satara facility of Meditab Specialities|work=The Economic Times|url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/rubicon-research-acquires-satara-facility-of-meditab-specialities/articleshow/84264915.cms|access-date=2021-08-24}}</ref> Meditab Specialities Limited is a wholly owned subsidiary of Cipla Limited. The Satara manufacturing facility is a state-of-the-art cGMP compliant and MHRA (UK) inspected production site.<ref>{{Cite web|date=2021-07-09|title=Rubicon Research acquires MeditabSpecialities’ facility in Satara, Maharashtra|url=https://www.expresspharma.in/rubicon-research-acquires-meditabspecialities-facility-in-satara-maharashtra/|access-date=2021-08-24|website=Express Pharma|language=en-US}}</ref><ref>{{Cite news|others=Special Correspondent|date=2021-07-09|title=Rubicon Research acquires Cipla arm’s oral liquid, nasal product unit|language=en-IN|work=The Hindu|url=https://www.thehindu.com/business/rubicon-research-acquires-cipla-arms-oral-liquid-nasal-product-unit/article35241995.ece|access-date=2021-08-24|issn=0971-751X}}</ref>

==Corporate structure==
<ref>Bloomsberg Businessweek: Rubicon Research Private Limited</ref>

*Ms. Pratibha Pilgaonkar, Co-founder, Managing Director
*Mr. Sudhir Pilgaonkar, Co-founder, Chief Commercial Officer
*Mr. Parag Sancheti. Chief Executive Officer
*Dr. L.S. Rao, Chief Scientific Officer
*Ms. Surabhi Sancheti, Senior Vice President
*Mr. KG Ananthakrishnan, Advisor

==References==
{{Reflist}}

[[Category:Companies based in Mumbai]]
[[Category:Pharmaceutical companies of India]]
[[Category:Pharmaceutical companies established in 1999]]
[[Category:1999 establishments in Maharashtra]]

Rubicon Research - Revision history

->Kahtar: Repair CS1 error(s), replaced: website=https://www. → website=www., removed stub tag